Fundraising FoxBiotech Startups
11,081 companies tagged Biotech, with their investors and founders.
0 investors
NED Biosystems develops patented, non-toxic combination cancer treatments using a systems biology approach targeting multiple disease pathways simultaneously. The company's lead program NED-170 is designed for late-stage cancer patients, particularly those who are heavily pre-treated, with a focus on achieving no evidence of disease while minimizing toxicity and side effects.
0 investors
NED Medical develops CombiSphere, a Y90 radioembolization therapy made with proprietary materials offering optimized particle size, density, radiopacity, and dosimetry to treat liver cancer. The product is aimed at clinicians treating oncology patients through embolization therapy.
0 investors
Skye Bioscience is a biotechnology company developing drugs that target the CB1 receptor to treat obesity and other metabolic diseases. Its lead candidate, nimacimab, is a CB1 receptor inhibitor in clinical development.
0 investors
0 investors
NeOnc is a biopharmaceutical company developing a patented platform technology to transport therapeutics across the blood-brain barrier, including intranasal delivery formulations such as NEO100 and NEO400. It targets brain and central nervous system diseases like glioblastoma and other brain cancers, serving patients and partnering with pharmaceutical companies.
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
Neuro-Kinesis develops biosensor-integrated surgical instruments that deliver real-time biological feedback to surgeons during procedures. The company focuses on catheter-based imaging tools and neurosurgical retractors designed to improve procedural outcomes in cardiac mapping, organ visualization, and brain surgery.
0 investors
MetaVia is a clinical-stage biotechnology company developing therapeutics for cardiometabolic diseases, including DA-1726 for obesity and vanoglipel (DA-1241) for Metabolic Dysfunction-Associated Steatohepatitis (MASH).
0 investors
0 investors
0 investors
NeuroCytonix operates a clinical research center in Monterrey, Mexico that develops and conducts investigational protocols for neurological conditions including cerebral palsy, autism, stroke, and traumatic brain injury. The center is designed to provide personalized clinical care and research in compliance with international good clinical practice standards.
0 investors
Neuroelectrics develops the Starstim platform, combining EEG monitoring headpieces, cloud-based delivery, and personalized protocols to deliver non-invasive Transcranial Electrical Stimulation (tES) neuromodulation therapy for brain disorders such as depression and epilepsy. It serves patients whose conditions are not controlled by drugs or surgery, as well as neuroscience researchers who use its tools for brain research.
0 investors
0 investors
0 investors
0 investors
NeuroInitiative is a computational biology company that uses a patented AI simulation platform to model neural molecular interactions and prioritize drug targets across aging biology and neurodegeneration. Its platform produced Vincere Biosciences' VB-23, a USP30 inhibitor Parkinson's disease therapy entering Phase 1 clinical trials in 2026.
0 investors
0 investors
NeuroNascent develops therapeutics aimed at generating new neurons and regenerating existing ones to treat neurological disorders. Its R&D pipeline targets conditions including Alzheimer's disease, Parkinson's disease, and developmental delay, alongside a veterinary medicine program.
0 investors